menu
    • menu
    [{"orgOrder":0,"company":"AlgoTherapeutix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Amitriptyline","moa":"Norepinephrine transporter","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"AlgoTherapeutix","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"AlgoTherapeutix \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"AlgoTherapeutix \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Amitriptyline","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Migraine Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Amitriptyline","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Undisclosed","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Migraine Research Foundation","highestDevelopmentStatusID":"1","companyTruncated":"Rambam Health Care Campus \/ Migraine Research Foundation"},{"orgOrder":0,"company":"University of Sao Paulo","sponsor":"Cristalia Produtos Quimicos Farma. Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Amitriptyline","moa":"Norepinephrine transporter","graph1":"Neurology","graph2":"Phase III","graph3":"University of Sao Paulo","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Sao Paulo \/ Cristalia Produtos Quimicos Farma. Ltda","highestDevelopmentStatusID":"10","companyTruncated":"University of Sao Paulo \/ Cristalia Produtos Quimicos Farma. Ltda"}]

    Find Clinical Drug Pipeline Developments & Deals for Laroxyl (TN)

    Menu

    Laroxyl (TN)

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AlgoTherapeutix

                            France arrow
                            Florida Innovation
                            Not Confirmed

                            AlgoTherapeutix

                            France arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amitriptyline

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AlgoTherapeutix Announces Orphan Drug Designation Granted by FDA for ATX01 in Erythromelalgia

                            Details : U.S. Food and Drug Administration (FDA) has granted ATX01 (proprietary topical amitriptyline) Orphan Drug Designation for the treatment of erythromelalgia. The ATX01 program primarily targets Chemotherapy-Induced Peripheral Neuropathy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 08, 2020

                            Lead Product(s) : Amitriptyline

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Sao Paulo

                            Country arrow
                            Florida Innovation
                            Not Confirmed

                            University of Sao Paulo

                            Country arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amitriptyline

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Cristalia Produtos Quimicos Farma. Ltda

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment of Neuropathic Pain in Leprosy

                            Details : Amitriptyline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Neuralgia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 27, 2017

                            Lead Product(s) : Amitriptyline

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Cristalia Produtos Quimicos Farma. Ltda

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rambam Health Care Campus

                            Israel arrow
                            Florida Innovation
                            Not Confirmed

                            Rambam Health Care Campus

                            Israel arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amitriptyline

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Migraine Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prediction of Migraine Prevention Efficacy Based on Individual's Pain Modulation

                            Details : Amitriptyline is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Migraine Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 02, 2014

                            Lead Product(s) : Amitriptyline

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Migraine Research Foundation

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rambam Health Care Campus

                            Israel arrow
                            Florida Innovation
                            Not Confirmed

                            Rambam Health Care Campus

                            Israel arrow
                            Florida Innovation
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amitriptyline

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Mechanism-based Choice of Therapy for Pain: Can Successful Prevention of Migraine be Coupled to a Psychophysic...

                            Details : Amitriptyline is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Migraine Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 13, 2010

                            Lead Product(s) : Amitriptyline

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth